GLG News by Niaspan Prescribers for Raising HDL

Exforge (valsartan/amlodipine) is likely to be well received by physicians who have been fond of Lotrel and prefer branded hypertensive therapies to generic agents.

The only available oral inhibitor of thrombin is warfarin which is a nightmare compound to deal with from a level and DDI standpoint.   

This article summarizes the DTC strategies used to encourage generic utilization for prescription therapies, changing the dynamic from the perception that these therapies are inferior but acceptable alternatives to branded therapies to the impression that these are superior from a consumer value st...

Much attention has been brought to HDL, its metabolism and potential for risk modification with HDL raising therapies.  With the demise of the CETP inhibitor torcetrapib (ILLUMINATE and ILLUSTRATE NEJM 2007; 356:1304-1316) and the ACAT inhibitor pactimibe in the ACTIVATE study (NEJM 354:1253-1263)...

This study compared Crestor 40 mg daily with a combination of Crestor and Zetia on getting patients to their LDL goals. Several of the results struck me: in my experience, I can usually get a larger percentage of patients to goal on monotherapy at lower doses of Crestor; this study and a number of others...

UNLOAD has provided additional information about the potential utility for ultrafiltration in the management of acutely decompensated patients with CHF admitted to the hospital for volume unloading routinely performed with IV diuretics.Although safety and efficacy may be superior to diuretic based regimens...

1.)  Excessive accumulation of fat in the liver is a common occurrence in obesity and obesity comorbidities, such as diabetes and dyslipidemia.  2.) There has been no useful therapeutic intervention to remove fat from excessive deposits in the liver of these patients.  3.) Excessive...

1.) Depression is very common among the obese population. 2.) Suppressors of cannabinoid receptors are suspect of causing depression because of the euphoric effect of cannibinoids.3.) Rimonabant when tested in thousands of patients, in comparison to placebo caused a very small statistically insignificantly...

By reducing fractional catabolic rate and by producing a large, cholesterol rich HDL molecule which could not easily be cleared by hepatic HDL receptors, our research group in Cincinnati thought from the beginning that the CETP inhibitors AS A CLASS would fail, and might even be proatherogenic. Regrettably,...

1.This study's results are the first clinical confirmation of the benefits of a single drug to reverse coronary deposits of cholesterol in patients after just 2 years of treatment with Rosuvastatin (Crestor). 2. These results originated further clinical trials which will be presented at the forthcoming...